Cargando…

A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles

Silver is a strong antibiotic that is increasingly incorporated into consumer products as a bulk, salt, or nanosilver, thus potentially causing side-effects related to human exposure. However, the fate and behavior of (nano)silver in the human body is presently not well understood. In order to aggre...

Descripción completa

Detalles Bibliográficos
Autores principales: Bachler, Gerald, von Goetz, Natalie, Hungerbühler, Konrad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771750/
https://www.ncbi.nlm.nih.gov/pubmed/24039420
http://dx.doi.org/10.2147/IJN.S46624
_version_ 1782284216867749888
author Bachler, Gerald
von Goetz, Natalie
Hungerbühler, Konrad
author_facet Bachler, Gerald
von Goetz, Natalie
Hungerbühler, Konrad
author_sort Bachler, Gerald
collection PubMed
description Silver is a strong antibiotic that is increasingly incorporated into consumer products as a bulk, salt, or nanosilver, thus potentially causing side-effects related to human exposure. However, the fate and behavior of (nano)silver in the human body is presently not well understood. In order to aggregate the existing experimental information, a physiologically based pharmacokinetic model (PBPK) was developed in this study for ionic silver and nanosilver. The structure of the model was established on the basis of toxicokinetic data from intravenous studies. The number of calibrated parameters was minimized in order to enhance the predictive capability of the model. We validated the model structure for both silver forms by reproducing exposure conditions (dermal, oral, and inhalation) of in vivo experiments and comparing simulated and experimentally assessed organ concentrations. Therefore, the percutaneous, intestinal, or pulmonary absorption fraction was estimated based on the blood silver concentration of the respective experimental data set. In all of the cases examined, the model could successfully predict the biodistribution of ionic silver and 15–150 nm silver nanoparticles, which were not coated with substances designed to prolong the circulatory time (eg, polyethylene glycol). Furthermore, the results of our model indicate that: (1) within the application domain of our model, the particle size and coating had a minor influence on the biodistribution; (2) in vivo, it is more likely that silver nanoparticles are directly stored as insoluble salt particles than dissolve into Ag(+); and (3) compartments of the mononuclear phagocytic system play a minor role in exposure levels that are relevant for human consumers. We also give an example of how the model can be used in exposure and risk assessments based on five different exposure scenarios, namely dietary intake, use of three separate consumer products, and occupational exposure.
format Online
Article
Text
id pubmed-3771750
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-37717502013-09-13 A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles Bachler, Gerald von Goetz, Natalie Hungerbühler, Konrad Int J Nanomedicine Original Research Silver is a strong antibiotic that is increasingly incorporated into consumer products as a bulk, salt, or nanosilver, thus potentially causing side-effects related to human exposure. However, the fate and behavior of (nano)silver in the human body is presently not well understood. In order to aggregate the existing experimental information, a physiologically based pharmacokinetic model (PBPK) was developed in this study for ionic silver and nanosilver. The structure of the model was established on the basis of toxicokinetic data from intravenous studies. The number of calibrated parameters was minimized in order to enhance the predictive capability of the model. We validated the model structure for both silver forms by reproducing exposure conditions (dermal, oral, and inhalation) of in vivo experiments and comparing simulated and experimentally assessed organ concentrations. Therefore, the percutaneous, intestinal, or pulmonary absorption fraction was estimated based on the blood silver concentration of the respective experimental data set. In all of the cases examined, the model could successfully predict the biodistribution of ionic silver and 15–150 nm silver nanoparticles, which were not coated with substances designed to prolong the circulatory time (eg, polyethylene glycol). Furthermore, the results of our model indicate that: (1) within the application domain of our model, the particle size and coating had a minor influence on the biodistribution; (2) in vivo, it is more likely that silver nanoparticles are directly stored as insoluble salt particles than dissolve into Ag(+); and (3) compartments of the mononuclear phagocytic system play a minor role in exposure levels that are relevant for human consumers. We also give an example of how the model can be used in exposure and risk assessments based on five different exposure scenarios, namely dietary intake, use of three separate consumer products, and occupational exposure. Dove Medical Press 2013 2013-09-02 /pmc/articles/PMC3771750/ /pubmed/24039420 http://dx.doi.org/10.2147/IJN.S46624 Text en © 2013 Bachler et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Bachler, Gerald
von Goetz, Natalie
Hungerbühler, Konrad
A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles
title A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles
title_full A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles
title_fullStr A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles
title_full_unstemmed A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles
title_short A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles
title_sort physiologically based pharmacokinetic model for ionic silver and silver nanoparticles
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771750/
https://www.ncbi.nlm.nih.gov/pubmed/24039420
http://dx.doi.org/10.2147/IJN.S46624
work_keys_str_mv AT bachlergerald aphysiologicallybasedpharmacokineticmodelforionicsilverandsilvernanoparticles
AT vongoetznatalie aphysiologicallybasedpharmacokineticmodelforionicsilverandsilvernanoparticles
AT hungerbuhlerkonrad aphysiologicallybasedpharmacokineticmodelforionicsilverandsilvernanoparticles
AT bachlergerald physiologicallybasedpharmacokineticmodelforionicsilverandsilvernanoparticles
AT vongoetznatalie physiologicallybasedpharmacokineticmodelforionicsilverandsilvernanoparticles
AT hungerbuhlerkonrad physiologicallybasedpharmacokineticmodelforionicsilverandsilvernanoparticles